Urinary Tract Infections

Infections requiring hospitalization were associated with increased risk for future incident heart failure, regardless of infection and HF subtype, according to new data published in the Journal of the American Heart Association.

Healio spoke with Cynthia Fok, MD, associate professor in the department of urology at the University of Minnesota Medical School, about the prevalence of urinary tract infections in U.S. women and the current treatments available.

Antibiotics remain the most common way to treat urinary tract infections, yet many women remain untreated because the condition is often overlooked or they do not receive appropriate testing and care.

The FDA approved pivmecillinam tablets to treat uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus for women, according to an agency press release.

The FDA approved pembrolizumab in combination with chemoradiotherapy for the treatment of certain women with stage III to stage IVA cervical cancer.

An analysis of phase 3 trials of patients with complicated UTIs found that having discordant outcomes at a test-of-cure visit — clinical success but microbiological failure — was associated with an increased risk for late clinical failure.